Clinic Roundup

NuPathe Inc., of Conshohocken, Pa., presented additional data from a 12-month open-label trial of migraine patch Zelrix (transdermal sumatriptan) at the American Headache Society annual scientific meeting. The drug was well tolerated, and new data showed 51 percent to 68 percent of patients reported headache relief, while 70 percent to 86 percent reported nausea relief.